Abstract
Low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. To overcome this problem, we describe here a semi-replication-competent retrovirus (s-RCR) in which the gag-pol and envelope (VSV-G, vesicular stomatitis virus G protein) genes were split into two vectors. This system offers potential advantages over both replication-defective vectors, in terms of efficiency of in vivo spread through a tumor, and all-in-one replication-competent vectors in terms of the payload of therapeutic genes that can be carried. We achieved a viral titer of s-RCR viruses approximately 70-fold higher than VSV-G pseudotyped, replication-defective vectors. In addition, s-RCR vectors induced tumor killing by the cytotoxicity of VSV-G during viral spread. Inclusion of the herpes simplex virus thymidine kinase (HSVtk30) gene into vectors significantly improved tumor killing activity followed by ganciclovir (GCV) treatment in vitro under conditions of low-level viral replication. However, at high levels of viral spread, VSV-G-mediated cytotoxicity predominated. Xenografts of human fibrosarcoma HT1080 cells, preinfected by semi-replicative green fluorescent protein vectors (semi-GFP), were completely non-tumorigenic in nude mice. Implantation of cells preinfected by semi-replicative TK30 vectors (semi-TK30) mixed with parental HT1080 cells at a ratio of 1:1 efficiently prevented tumor growth in mice treated by GCV. Direct intratumoral injection of HT1080 tumors growing in nude mice, or B16 murine melanoma in immunocompetent mice, with semi-TK30 viruses significantly prolonged survival. Injection of autologous cells (B16) producing semi-TK30 vector into B16 tumors prolonged survival only in mice treated with GCV but not with phosphate-buffered saline (PBS). In contrast, when xenogeneic cells (293T) producing semi-TK30 vectors were injected into B16 tumors, an optimal survival advantage was obtained in mice treated with PBS rather than GCV. These data indicate that complex interactions exist between direct cytotoxicity of VSV-G and HSVtk expression when placed in the context of additional immune parameters, which combine to determine the efficacy of the therapy. Taken together, our data suggest that s-RCR vectors have some potential advantages for development to deliver genes into tumors for cancer treatment but that a combination of factors will impact on the decision as to whether the s-RCR strategy is worth developing to full clinical trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK . Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033–8037.
Howard BD, Boenicke L, Schniewind B, Henne-Bruns D, Kalthoff H . Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther 2000; 7: 927–938.
Lee H, Song JJ, Kim E, Yun CO, Choi J, Lee B et al. Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumor. Gene Therapy 2001; 8: 268–273.
Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276–5281.
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM . In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–1552.
Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274–5283.
Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH . In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83–88.
Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D . Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024–7028.
Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354–1361.
Rainov NG . A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389–2401.
Beck C, Cayeux S, Lupton SD, Dorken B, Blankenstein T . The thymidine kinase/ganciclovir-mediated ‘suicide’ effect is variable in different tumor cells. Hum Gene Ther 1995; 6: 1525–1530.
Sturtz FG, Waddell K, Shulok J, Chen X, Caruso M, Sanson M et al. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy. Hum Gene Ther 1997; 8: 1945–1953.
Laird DW, Fistouris P, Batist G, Alpert L, Huynh HT, Carystinos GD et al. Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Res 1999; 59: 4104–4110.
Solly SK, Trajcevski S, Frisen C, Holzer GW, Nelson E, Clerc B et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 2003; 10: 30–39.
Wang WJ, Tai CK, Kasahara N, Chen TC . Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 2003; 14: 117–127.
Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002; 62: 5495–5504.
Eslahi NK, Muller S, Nguyen L, Wilson E, Thull N, Rolland A et al. Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy. Cancer Gene Ther 2001; 8: 55–62.
Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell–tumor cell hybrid vaccines. Nat Med 2003; 9: 1215–1219.
Riviere I, Brose K, Mulligan RC . Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733–6737.
Qiao J, Roy V, Girard MH, Caruso M . High translation efficiency is mediated by the encephalomyocarditis virus internal ribosomal entry sites if the natural sequence surrounding the eleventh AUG is retained. Hum Gene Ther 2002; 13: 881–887.
Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T . A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91: 9564–9568.
Germain E, Roullin VG, Qiao J, de Campos Lima PO, Caruso M . RD114-pseudotyped retroviral vectors kill cancer cells by syncytium formation and enhance the cytotoxic effect of the TK/GCV gene therapy strategy. J Gene Med 2004; 7: 389–397.
Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N . Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J Virol 2001; 75: 6989–6998.
Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D . Immune response to green fluorescent protein: implications for gene therapy. Gene Therapy 1999; 6: 1305–1312.
Bubnic SJ, Nagy A, Keating A . Donor hematopoietic cells from tansgenic mice that express GFP are immunogenic in immunocompetent recipients. Hematology 2005; 10: 289–295.
Vile RG, Hart IR . Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860–3864.
Sliva K, Erlwein O, Bittner A, Schnierle BS . Murine leukemia virus (MLV) replication monitored with fluorescent proteins. Virol J 2004; 1: 14.
Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–256.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–419.
Qiao J, Diaz RM, Vile RG . Success for gene therapy: render unto Caesar that which is Caesar's. Genome Biol 2004; 5: 237.
Trajcevski S, Solly SK, Frisen C, Trenado A, Cosset FL, Klatzmann D . Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors. J Gene Med 2005; 7: 276–287.
Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N . A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther 2001; 12: 921–932.
Vogt B, Roscher S, Abel B, Hildinger M, Lamarre A, Baum C et al. Lack of superinfection interference in retroviral vector producer cells. Hum Gene Ther 2001; 12: 359–365.
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.
Mineta T, Rabkin SD, Martuza RL . Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963–3966.
Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821–825.
Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–1334.
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK . High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430–7436.
Black ME, Newcomb TG, Wilson HM, Loeb LA . Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996; 93: 3525–3529.
Qiao J, Black ME, Caruso M . Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11: 1569–1576.
Qiao J, Caruso M . PG13 packaging cells produce recombinant retroviruses carrying a diphtheria toxin mutant which kills cancer cells. J Virol 2002; 76: 7343–7348.
Altman DG . Analysis of survival times. In: Practical Statistics for Medical Research 1991: Chapman and Hall: London, pp 365–395.
Acknowledgements
This work was supported in part by the Mayo Foundation, the Susan G Komen Breast Cancer Foundation and the National Institutes of Health (CA 85931). We thank Toni L Higgins for secretarial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qiao, J., Moreno, J., Sanchez-Perez, L. et al. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther 13, 1457–1470 (2006). https://doi.org/10.1038/sj.gt.3302782
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302782
Keywords
This article is cited by
-
Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy
Archives of Virology (2020)
-
Adenovirus–Retrovirus Hybrid Vectors Achieve Highly Enhanced Tumor Transduction and Antitumor Efficacy In Vivo
Molecular Therapy (2011)
-
Selective gene silencing by viral delivery of short hairpin RNA
Virology Journal (2010)
-
Induction of cytopathic effects and apoptosis in Spodoptera frugiperda cells by the HIV-1 Env glycoprotein signal peptide
Virus Genes (2010)
-
Tumor Anti-angiogenic Gene Therapy with Microencapsulated Recombinant CHO Cells
Annals of Biomedical Engineering (2007)